BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T052313
CREATED:20240828T105923Z
LAST-MODIFIED:20240828T105923Z
UID:39639-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:With recent accelerated approval wins\, positive clinical trial readouts\, progression through clinical pipelines and exciting mergers and acquisitions\, it has certainly been an industry-defining year for the rare and genetic renal space. \nIn the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients\, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry\, academic KOL\, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations. \nJoin Mironid\, AstraZeneca\, Novartis\, Maza Therapeutics\, Harvard Medical School\, and more as you dive into critical topics investigating IgAN\, FSGS\, PKD\, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need. \nView the full event program here: https://ter.li/ncjxqh
URL:https://www.pharmajournalist.com/event/4th-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T052313
CREATED:20240719T112018Z
LAST-MODIFIED:20240722T133910Z
UID:39410-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:2nd Covalent Drug Discovery & Development Summit
DESCRIPTION:Discover & Develop Selective\, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology\, Immunology & Beyond \nThe covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology\, immunology and CNS. Yet\, key challenges remain in balancing reactivity and sensitivity\, de-risking the ligandability of alternative residues\, and tackling PKPD disconnects and efficiency bottlenecks\, \nBringing together 100+ covalency experts\, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics. \n\nDates: December 10-12\, 2024\nLocation: Hilton Boston Logan Airport\, Boston\, Massachusetts\nEvent Program: https://ter.li/bz5jjg\n\nDive into extensive technical content spanning target selectivity\, hit screening\, lead optimization and covalent warhead design\, network with over 100 heads\, directors and VPs of Proteomics\, Medicinal Chemistry\, Chemical Biology\, Discovery Biology and Pharmacology\, and hear from the brightest minds of academia as they share their latest findings. \nDownload the program here: https://ter.li/bz5jjg \nRegister your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/8257lj
URL:https://www.pharmajournalist.com/event/2nd-covalent-drug-discovery-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T052313
CREATED:20240919T065329Z
LAST-MODIFIED:20240920T112649Z
UID:39788-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:5th Genome Editing Therapeutics Summit
DESCRIPTION:Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery\, Casgevy marks the first approved gene-editing therapy\, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases\, with a rapidly growing pipeline of precision genome-editing techniques emerging. \n \nThe 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations\, expert panels\, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases\, base and prime editing\, multiplex editing\, and precision tools enabling small and large genome modifications. Additionally\, it will highlight epigenome editing\, recombinase and transposon-based technologies\, and innovative delivery vehicles. \nOver three days\, industry and academic leaders will present the latest research on cutting-edge therapies\, discussing the safety\, precision\, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first\, with a strong focus on creating robust safety profiles\, detecting off-target effects\, and facilitating investigational new drug (IND) filings. \nParticipants will gain actionable insights to improve the precision and safety of their technologies\, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs. \nJoin us and be part of the gene-editing revolution shaping the future of therapeutic development!
URL:https://www.pharmajournalist.com/event/5th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T052313
CREATED:20240809T123626Z
LAST-MODIFIED:20240813T083728Z
UID:39561-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:Personalized Vaccine Summit
DESCRIPTION:The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA\, DNA\, peptides\, viral\, dendritic cell and more to share how they are conquering common challenges\, developing novel bioinformatic strategies\, and achieving clinical efficacy. \nThis is the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal – cure cancer! Join the likes of BioNTech\, CureVac\, Imvax\, NousCom\, with our expert speaker faculty of leaders and industry pioneers\, for 3 days of content and 15+ deep dive case studies. \nInterested? Find out more here. https://ter.li/lg5a1h
URL:https://www.pharmajournalist.com/event/personalized-vaccine-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T052313
CREATED:20240808T111110Z
LAST-MODIFIED:20240808T111110Z
UID:39549-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:6th Cell Therapy Analytical Development Summit
DESCRIPTION:As the field of cell therapy evolves\, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials\, leading to more efficient regulatory approval. \nWhy Attend? \n\nExplore the latest advancements in immunophenotype\, cell-based\, and molecular assays.\nConnect with over 40 industry leaders and experts from companies like Bristol Myers Squibb\, Takeda\, and Kite Pharma to delve into assay matrices\, phase-appropriate development\, and specifications.\nParticipate in discussions on overcoming challenges in product characterization\, assay development\, and scale-up\, sharing innovative technologies and best practices to advance cell therapies.\n\nJoin us to elevate the development of safe and effective autologous and allogeneic cell therapies to new heights! \nDownload the NEW 2024 program
URL:https://www.pharmajournalist.com/event/6th-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241202
DTEND;VALUE=DATE:20241205
DTSTAMP:20260515T052313
CREATED:20240808T110905Z
LAST-MODIFIED:20240808T110905Z
UID:39544-1733097600-1733356799@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. \nThis year’s agenda brings you the opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication. Leading experts including Cartesian Therapeutics\, Bristol Myers Squibb\, the University of Pennsylvania\, ImmPACT Bio and more\, will cover their latest clinical updates\, next-generation candidates\, novel antigen targets\, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease. \nThis is your chance to connect with top cell therapy pioneers\, clinicians\, investors\, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment. \nFind out more here.
URL:https://www.pharmajournalist.com/event/2nd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241126
DTEND;VALUE=DATE:20241129
DTSTAMP:20260515T052313
CREATED:20240906T130002Z
LAST-MODIFIED:20240906T130002Z
UID:39730-1732579200-1732838399@www.pharmajournalist.com
SUMMARY:GPCRs-Targeted Drug Discovery Summit Europe
DESCRIPTION:As structural biology tools and screening technologies advance\, the GPCR super family continues to be a hot area of drug discovery\, with the potential to treat a plethora of diseases. For the first time ever\, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London\, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery. \nThis November\, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data\, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias\, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug discovery across inflammatory\, cardiovascular and metabolic indications and beyond. \nBringing together technical experts from Eli Lilly\, AstraZenenca\, Roche\, ThirtyFiveBio\, OMass Therapeutics and more\, this Meeting aims to unlock previously undruggable targets\, reveal the significance of genetic variants of GPCRs\, showcase ground-breaking drug discovery tools and streamline the translation of small molecules and biologics into clinically successful therapies. \nJoin 70+ Senior Scientists\, Heads and Directors of Drug Discovery\, Biology\, Chemistry and Pharmacology for 3 days of technical and data driven case studies and discussions\, enabling you and your team to accelerate novel GPCR-targeted drug discovery. \nTo know more visit: https://ter.li/os0qc7
URL:https://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit-europe/
LOCATION:Millennium Hotel and Conference Centre Gloucester\, 4-18 Harrington Gardens\, South Kensington\, London\, SW7 4LH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241121
DTEND;VALUE=DATE:20241123
DTSTAMP:20260515T052313
CREATED:20240904T114349Z
LAST-MODIFIED:20240904T121218Z
UID:39681-1732147200-1732319999@www.pharmajournalist.com
SUMMARY:3rd Liquid Biopsy Surveillance Summit
DESCRIPTION:Liquid biopsies are revolutionizing clinical trials\, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification\, ensuring they receive the most effective and safe treatments. The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments. \n \nExpect to hear critical insights from leading biopharma\, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials\, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond. \nJoin your peers from Biomarker\, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes. \nThis event is free to attend* if you work for a drug developer\, researcher\, or academic institution. \nDownload the event guide for full details: https://ter.li/ig2qtr \n*View the website for full T&Cs: https://ter.li/h7ri3w
URL:https://www.pharmajournalist.com/event/3rd-liquid-biopsy-surveillance-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241120
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T052313
CREATED:20240920T113804Z
LAST-MODIFIED:20240924T114350Z
UID:39796-1732060800-1732233599@www.pharmajournalist.com
SUMMARY:Portfolio Strategy & Decision Making for Biopharma Summit
DESCRIPTION:Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit – the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s dynamic market. \nGain exclusive insights into leveraging advanced data analytics\, forecasting tools\, and innovative approaches to enhance decision-making. This summit will showcase real-world case studies and best practices from both established big pharma and agile biotech companies\, helping you navigate market volatility with confidence. \nNetwork with over 60 industry leaders and engage in discussions focused on boosting cross-functional collaboration and exploring partnership opportunities. Learn how to align stakeholders\, mitigate risks\, and drive sustainable growth through strategic portfolio management. \nIn an era of rapid change and unprecedented challenges in the biopharma market\, this event is essential for staying ahead. Don’t miss the opportunity to equip yourself with the tools and knowledge to adapt\, respond\, and implement strategies that ensure portfolio success. \nKey Themes Include: \n\nAdvanced data analytics for better decision-making\nRisk mitigation and portfolio optimization\nCross-functional collaboration and partnerships\n\nJoin us to analyze\, adapt\, and respond to today’s biopharma challenges—position yourself for success!
URL:https://www.pharmajournalist.com/event/portfolio-strategy-decision-making-for-biopharma-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T052313
CREATED:20240806T120430Z
LAST-MODIFIED:20240809T122433Z
UID:39503-1731974400-1732147199@www.pharmajournalist.com
SUMMARY:LEAP HR: Emerging Biopharma
DESCRIPTION:Mark your calendars for November because LEAP HR: Emerging Biopharma is back! Returning to Boston from November 19-20\, this event is designed specifically for CHROs\, CPOs\, and Heads of HR at the heart of Emerging Biopharma organizations. Over the course of two days\, we will unite the most senior leaders from Emerging Biopharma companies across the US for unmissable content and invaluable networking opportunities. \nIn today’s rapidly evolving biotech landscape\, there has never been a more crucial time for HR leaders to come together. With limited resources and funding\, the challenges are greater than ever. LEAP HR: Emerging Biopharma provides a platform to address these challenges head-on\, offering strategies to enhance HR efficiency and prepare for a future brimming with investment and growth opportunities. \nThis event is your best opportunity to delve deeply into the pressing issues that senior leaders face daily. Topics will include rethinking organizational efficiencies\, adapting to new agile working methodologies\, and genuinely engaging and retaining critical biopharma talent. Through a series of insightful sessions\, participants will explore how to build high-impact strategies that align closely with business needs and help navigate today’s volatile biotech market. \nUnveiling of 30+ case studies showcasing how HR leaders are overcoming industry challenges\, gain actionable insights into engaging and developing employees\, retaining essential talent\, and preparing for future adversities. By sharing these real-world examples\, you will leave equipped with the tools you need to foster resilience and innovation within their organizations. \nJoin us in Boston this November for LEAP HR: Emerging Biopharma and become part of a dynamic community of HR leaders dedicated to shaping the future of the biopharma industry. Don’t miss this chance to network with peers\, gain fresh perspectives\, and develop strategies that will help your organization thrive in an increasingly competitive market. Be prepared to return to your organization with renewed energy and practical solutions to drive success in the challenging yet promising world of Emerging Biopharma. \nFind out more now: https://ter.li/jqplmd
URL:https://www.pharmajournalist.com/event/leap-hr-emerging-biopharma/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T052313
CREATED:20240805T115824Z
LAST-MODIFIED:20240805T115824Z
UID:39492-1731974400-1732233599@www.pharmajournalist.com
SUMMARY:8th Antifibrotic Drug Development Summit
DESCRIPTION:The landmark FDA approval of the first MASH therapeutic\, the orphan drug designation for systemic sclerosis trials\, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. Now more than ever experts are doubling down on fibrosis. \nAs the focus on innovative therapies intensifies\, there is a pressing need for cutting-edge strategies that can overcome preclinical and clinical challenges has never been more critical. With that\, I’m delighted to announce the return of the 𝗔𝗻𝘁𝗶𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 for its 𝟴𝘁𝗵 𝘆𝗲𝗮𝗿 as the fibrosis community’s premier event\, uniting industry experts and key opinion leaders across Pulmonology\, Hepatology\, Rheumatology\, Nephrology\, Cardiology\, and Gastroenterology. \nGathering decision makers to share cross fibrosis insights on innovative strategies to navigate the shared fibrosis challenges from discovery to novel targets\, preclinical models\, biomarkers\, and early-stage clinical trials. Gain exclusive insights and strategies to apply to your own research accelerating the development of truly transformative\, disease-modifying\, ‘antifibrotic’ therapeutics. \nWhether focusing on 𝗜𝗣𝗙\, 𝗠𝗔𝗦𝗛\, 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝘀𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀\, 𝗸𝗶𝗱𝗻𝗲𝘆 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝗻𝗴 𝗜𝗕𝗗 or 𝗮𝗻𝗼𝘁𝗵𝗲𝗿\, this summit is your collective forum to propel innovative and efficacious antifibrotic therapeutics to patients in need. \nJoin us at the 8th AFDD Summit to be part of the conversation\, share your insights\, and discover the innovations that are transforming fibrosis treatment. \nTo know more visit: https://ter.li/01itbv
URL:https://www.pharmajournalist.com/event/8th-antifibrotic-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241118
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T052313
CREATED:20240808T110613Z
LAST-MODIFIED:20240808T110613Z
UID:39537-1731888000-1732147199@www.pharmajournalist.com
SUMMARY:2nd Donor Selection & Cell Source Summit
DESCRIPTION:Join us at the 2nd Donor Selection & Cell Source Summit – an unparalleled event dedicated to revolutionizing donor testing\, screening\, and cell source selection. This is your chance to be at the forefront of scalable allogeneic manufacturing and streamline both supply chain and process development. \nWhy Attend? \n\nDive Deep: Explore the latest global regulatory requirements and donor testing innovations.\nCutting-Edge Insights: Learn about breakthrough genome sequencing data transforming donor selection.\nForge Connections: Network with leading companies like Bristol Myers Squibb\, ImmuneBridge\, and Deverra Therapeutics.\nExclusive Access: Discover strategies to partner with donation sites and secure access to elite donor pools.\n\nBy refining our donor selection processes today\, we can revolutionize the future of allogeneic therapies and significantly enhance patient outcomes. \nLearn more here.
URL:https://www.pharmajournalist.com/event/2nd-donor-selection-cell-source-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241113
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T052313
CREATED:20240815T164748Z
LAST-MODIFIED:20240819T230624Z
UID:39587-1731456000-1731628799@www.pharmajournalist.com
SUMMARY:World Companion Diagnostics & Liquid Biopsy Summit APAC
DESCRIPTION:In the last 12 months\, precision healthcare in the Asia-Pacific region has seen a surge in technology advancements\, including NGS and laboratory developed tests\, approvals such as a companion diagnostic test for lung cancer\, and evolving regulations throughout the region. \nThe World Companion Diagnostics & Liquid Biopsy Summit APAC has been put together to provide a dedicated forum for key stakeholders from biopharma\, diagnostic providers and leading academics to overcome critical challenges in liquid biopsy and companion diagnostic (CDx) testing. \n\nWhere: Conrad Centennial\, Singapore\nWhen: November 13-14\, 2024\nWho: 100+ precision medicine experts from across the APAC region and wider globe\n\nDownload the event agenda here: https://ter.li/3qxsp8 \nThis unique and important forum is uniting experts from Singapore\, Australia\, China\, Japan\, Taiwan\, the USA and more to create a comprehensive framework for successful drug-companion diagnostic co-development and robust biomarker testing to accelerate patient access to personalized healthcare for improved outcomes in the APAC market. \nThis conference is FREE* to attend for drug developers and academics\, see the website for full terms and conditions here: https://ter.li/ewpxoe
URL:https://www.pharmajournalist.com/event/world-companion-diagnostics-liquid-biopsy-summit-apac/
LOCATION:Conrad Centennial\, 2 Temasek Blvd\, Singapore\, 038982\, Singapore
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T052313
CREATED:20240906T115503Z
LAST-MODIFIED:20240906T115503Z
UID:39712-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Advanced Therapies USA
DESCRIPTION:The Advanced Therapies Congress showcases the future of advanced therapies. Bringing Europe’s largest cell and gene therapy conference and exhibition to Philadelphia\, the event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. This year\, we will be expecting 1000+ attendees\, 200 speakers\, 100+ sponsors and exhibitors\, join us now! \nTo know more visit: www.terrapinn.com/adtusa/pj/index 
URL:https://www.pharmajournalist.com/event/advanced-therapies-usa/
LOCATION:Pennsylvania Convention Center\, Philadelphia
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T052313
CREATED:20240815T164037Z
LAST-MODIFIED:20240815T164037Z
UID:39582-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:8th Dermatology Drug Development Summit
DESCRIPTION:The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion\, as Johnson & Johnson make a $3.35B play for bispecific candidates\, Alumis secured $259M series C and Galderma\, Incyte\, and Eli Lilly unveil late-breaking data. \nWith a fast-evolving drug development landscape\, remaining at the forefront of promising targets is now more crucial than ever. That’s why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston\, MA)\, the definitive industry-led forum uniting 130+ large pharma\, biotech\, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease. \nExplore the end-to-end conference program here: https://ter.li/5j7wx4 \nFeaturing 30+ expert speakers from the likes of Alys Pharmaceuticals\, LEO Pharma\, Incyte and AbbVie\, program highlights include: \n\n2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy\, providing more depth of content supporting disease pathogenesis understandings and novel target validation\, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges\n4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa\, JAK Inhibitors and Assets Targeting Multiple Indications\, plus laying foundations for Recruitment and Retention finesse.\n\nIncreased drug development landscape visibility\, including clinical case studies from early to late-stage programs\, all with dedicated Q&A time\, for Monoclonal Antibodies\, Oral and Topical Small Molecules\, Oral Peptides\, siRNA Lipid Conjugates\, Bispecific Antibodies and more! \nHere’s a snapshot of who you will meet: \nTakeda | MoonLake Immunotherapeutics | Seagen | Astria Therapeutics | Aditum Bio | Shaperon | Lynk Pharma | CAGE Bio | Sanofi | Edesa Biotech | Arcutis Biotherapeutics | AbbVie | GSK | Carocell Bio | Enveda Biosciences | Zura Bio | Incyte | UNION Therapeutics | Merck | Hudson Therapeutics | J&J | LEO Pharma | Recludix Pharma | Lynk Pharmaceuticals \nStay ahead of the scientific and commercial challenges in inflammatory disease drug development to set yourself up for success in 2025! \nQuick links: Website | Event Guide | Contact Us
URL:https://www.pharmajournalist.com/event/8th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T052313
CREATED:20240805T120321Z
LAST-MODIFIED:20240805T120321Z
UID:39498-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:Hit ID Summit
DESCRIPTION:Discover the future of drug discovery at the inaugural Hit ID Summit! As chemical libraries and hit screening methods—including DNA-encoded libraries\, high-throughput screening\, fragment-based screening\, and AI—continue to evolve\, now is the time for medicinal chemists\, computational chemists\, and drug discovery leaders and innovators to unite at a dedicated forum. This unique event presents the opportunity to share innovative ideas and actionable insights that will revolutionize hit finding strategies and propel the entire drug development process forward. From delving into the latest hit-finding technologies and methodologies\, bridging the gap from target identification to molecule discovery and transforming hits into promising leads. \nJoin us for an unmissable experience where the biggest names in pharma and biotech come together including AstraZeneca\, Bristol Myers Squibb\, GlaxoSmithKline\, Insitro\, Sanofi & more. This is your chance to stay ahead of the curve and drive innovation in your hit identification and drug discovery strategies. \nDon’t miss out on this unique opportunity to network with over 50 hit strategy specialists and drug discovery experts. With insights from industry giants like AbbVie\, AstraZeneca\, Novartis\, Pfizer\, Sanofi\, and UCB\, gain invaluable knowledge and forge meaningful connections that will take your work to the next level. \nTo know more visit: https://ter.li/fifhhn%20
URL:https://www.pharmajournalist.com/event/hit-id-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T052313
CREATED:20240719T120908Z
LAST-MODIFIED:20240719T120908Z
UID:39429-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Autoimmunity Pharma & Biotech Partnering Summit
DESCRIPTION:Spurred by George Schett and Andreas Mackensen’s remarkable CAR-T results in SLE\, the immunotherapy revolution for autoimmune diseases is the next “million-dollar question”. \nThe Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind\, laying enabled partnering on top of hyper-relevant scientific discussion specifically for immune reset and reconstitution therapies. \nVIEW THE FULL EVENT GUIDE \n60+ attending companies across modalities so pharma can decide which horse to back in this quickly evolving space \n1-2-1 meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers \n15 big pharma leads across business development\, search and evaluation\, immunology research and venture giving the best\, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy \n100% alignment on interests and intentions\, increasing the surface area for synergy in research and collaboration goals \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/autoimmunity-pharma-biotech-partnering-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241030
DTEND;VALUE=DATE:20241102
DTSTAMP:20260515T052313
CREATED:20240719T115454Z
LAST-MODIFIED:20240719T115454Z
UID:39424-1730246400-1730505599@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development & CMC Summit
DESCRIPTION:Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases\, including the first ever gene edited therapeutic. The CMC package required to effectively demonstrate safety and efficacy of increasingly complex gene therapy products to regulators needs to keep pace. \nThe 6th Gene Therapy Analytical Development & CMC Summit will unite 250+ analytical development\, CMC\, QC\, and process development experts to showcase innovative analytical and process development methods\, assess their readiness\, and ultimately guarantee safety\, quality\, efficacy\, and consistency of gene therapies to regulators. \nVIEW THE FULL EVENT GUIDE \nJoin your peers this July to: \n\nUnderstand how to transition your potency assay from early to late-stage\nExplore how NGS methods can better inform your genome titers\nAccurately measure partials in your samples\nProduce contaminant-free and high yield vector batches at scale\n\nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-cmc-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241101
DTSTAMP:20260515T052313
CREATED:20240807T112944Z
LAST-MODIFIED:20240807T113009Z
UID:39511-1730073600-1730419199@www.pharmajournalist.com
SUMMARY:7th TPD & Induced Proximity Summit
DESCRIPTION:With a flurry of high capital collaborations and partnership deals from the likes of C4T\, Merck KgGA\, Monte Rosa\, Proxygen\, Orum\, and momentum building in clinic with BTK degraders\, ER degraders and many more assets. It has never been more import to re-join forces at the 7th TPD & Induced Proximity Summit\, the longest standing and most comprehensive protein degradation and proximity based conference. \nSpanning foundational research and discovery\, through to IND-filing and clinical trials\, this is the world’s definitive meeting to discuss opportunities and challenges the TPD & Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders\, blockers\, stabilizers and inducers of protein-protein interactions. Whether you’re entering the space for the first time or a well-seasoned TPD veteran\, this forum will equip you with the knowhow and connections to make rapid advances in your work. \nThe 85+ industry expert speakers include: \n\nAlessio Ciulli\, Founder & Director\, Centre for Targeted Protein Degradation (University of Dundee)\nStuart Schreiber\, Founding Chief Executive Officer\, Arena Bioworks\nSharon Townson\, Chief Scientific Officer\, Monte Rosa Therapeutics\nNello Mainolfi\, Founder\, President & Chief Executive Officer\, Kymera Therapeutics\nAdrian Gottschalk\, Chief Executive Officer\, Foghorn Therapeutics\nAndrew Hirsch\, Chief Executive Officer\, C4 Therapeutics\nArthur T. Sands\, Chief Executive Officer\, Nurix Therapeutics\nChinatsu Sakata-Sakur\, Vice President\, Astellas Pharma\n\nAssembling over 500 TPD & Induced Proximity enthusiasts from across every corner of the landscape\, we have left no stone unturned to deliver the full breadth and depth of protein degradation and modulation research with SureTACs\, EpiTACs\, RIPTACs\, Molecular Gates\, and so much more. \nView the agenda here: https://ter.li/8nvx3c
URL:https://www.pharmajournalist.com/event/7th-tpd-induced-proximity-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260515T052313
CREATED:20240718T090741Z
LAST-MODIFIED:20240924T114834Z
UID:39393-1730073600-1730332799@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:𝘞𝘢𝘯𝘵 𝘵𝘰 𝘜𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥 𝘎𝘶𝘪𝘥𝘢𝘯𝘤𝘦\, 𝘚𝘵𝘳𝘦𝘢𝘮𝘭𝘪𝘯𝘦 𝘚𝘶𝘣𝘮𝘪𝘴𝘴𝘪𝘰𝘯𝘴\, & 𝘖𝘣𝘵𝘢𝘪𝘯 𝘈𝘱𝘱𝘳𝘰𝘷𝘢𝘭? \nThe knowledge and connections you gain at the 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 will make the difference between success and delay in your IND and BLA applications. You’ll hear from top regulatory experts like David Uguen (𝗢𝗿𝗰𝗵𝗮𝗿𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀)\, Shirley Bartido (𝗧𝗮𝗸𝗲𝗱𝗮 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀)\, Yao-Yao Zhu (𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮)\, and many more. \n  \n𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗯𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗵𝗲𝗿𝗲 – https://ter.li/8bp1bf \nIn the fast-evolving world of cell and gene therapy\, staying ahead of regulatory changes is critical. The stakes are high\, and your applications need to be flawless to speed up approval and bring life-saving therapies to patients faster. \nThe 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 will offer you the chance to: \n\nStay updated on evolving regulatory guidance\nLearn from real-world case studies\nExplore new CMC guidance\n\n… and more! \n𝗦𝗲𝗲 𝗮𝗹𝗹 𝗼𝗳 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗲𝘃𝗲𝗻𝘁 𝗵𝗮𝘀 𝘁𝗼 𝗼𝗳𝗳𝗲𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 – https://ter.li/8bp1bf \nDon’t miss out on your chance to navigate the complex regulatory landscape and accelerate your therapeutic pipelines at this meeting!
URL:https://www.pharmajournalist.com/event/cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241022
DTEND;VALUE=DATE:20241025
DTSTAMP:20260515T052313
CREATED:20240805T120043Z
LAST-MODIFIED:20240805T120043Z
UID:39495-1729555200-1729814399@www.pharmajournalist.com
SUMMARY:5th CFC Summit
DESCRIPTION:The 5th Commercializing Flow Chemistry Summit marks a pivotal year\, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing industry. This summit zeroes in on advanced scale-up capabilities and stakeholder engagement strategies\, responding to a market that is rapidly expanding and forecasted to reach US $4.6 billion by 2032. Attendees will delve into specialized sessions that focus on late–stage process development\, enhanced regulatory compliance\, and innovative manufacturing techniques like electrochemistry and continuous processing. \nThis event is crucial for professionals aiming to stay ahead in an industry moving towards more sustainable and efficient production methods. With a fresh emphasis on practical\, application-focused content\, the summit provides essential insights and networking opportunities\, making it a must-attend event for those looking to drive technical and strategic decision-making in their organizations. \nTo know more visit: https://ter.li/wiczxd
URL:https://www.pharmajournalist.com/event/5th-cfc-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241022
DTEND;VALUE=DATE:20241025
DTSTAMP:20260515T052313
CREATED:20240524T114253Z
LAST-MODIFIED:20240719T125514Z
UID:39167-1729555200-1729814399@www.pharmajournalist.com
SUMMARY:6th Annual TIL Therapies Summit
DESCRIPTION:Following the watershed approval of Iovance’s Lifileucel\, all eyes are now on TIL therapies as the up-and-coming major therapeutic avenue for solid tumor treatment. Introducing the 6th Annual TIL Therapies Summit! With 30+ expert speakers\, 12 new speaker companies\, 2 brand-new content-filled tracks and 2 brand-new interactive workshops\, you won’t want to miss out! \nHear from TIL industry leaders like Iovance\, MD Anderson Cancer Center\, Obsidian Therapeutics\, Steven Rosenberg’s group from the National Institute of Health and more\, as they share ground-breaking TIL discoveries from R&D to commercialization. \nJoin us in October to capitalize on this golden opportunity to ensure you and your entire team stay ahead of the TIL wave!
URL:https://www.pharmajournalist.com/event/6th-annual-til-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241015
DTEND;VALUE=DATE:20241017
DTSTAMP:20260515T052313
CREATED:20240607T121643Z
LAST-MODIFIED:20240607T121643Z
UID:39244-1728950400-1729123199@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma & Patient USA 2024
DESCRIPTION:Are you listening to your patient community? It’s not enough. Standing in the shadows and harvesting anecdotal insights won’t build connections\, create first-hand knowledge or illuminate your impact to internal stakeholders. \n \nWe must step forward and be visible\, actively engaging in patient communities and embedding the patient voice internally. YOU are the patient advocate in your company\, so overturn tokenistic gestures into meaningful actions that prioritise patients over patents. \nThis starts now. You must integrate and co-create from the outset\, from clinical design to commercial execution to boost adherence\, trial participation and create exceptional outcomes. Show that pharma is driven by more than profit – to build a world that empowers all patients and leaves no one in the dark. THIS is the real value of your work. \nWelcome to Pharma & Patient USA\, the co-created event for patient champions in pharma\, who won’t sit back. This October you will engage with leading pharma executives and patient advocates to learn first-hand how to drive change that will build a brighter and more inclusive future in healthcare. \nAre you ready to be the new beacon of trust? Join us to be in the room\, be visible and be engaged.
URL:https://www.pharmajournalist.com/event/reuters-events-pharma-patient-usa-2024/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Reuters Events":MAILTO:kana.hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241014
DTEND;VALUE=DATE:20241016
DTSTAMP:20260515T052313
CREATED:20240613T152904Z
LAST-MODIFIED:20240613T152904Z
UID:39260-1728864000-1729036799@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices UK
DESCRIPTION:SAE Media Group’s 5th Annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent\, high volume and viscous drugs grow. \n \nThe conference will also cover key regulatory updates such as guidance on MDR requirements from regulatory and notified bodies\, and the importance of considering user-experience and developing patient-centric devices. The two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas. \nWhy  attend: \n\n2 full days of networking opportunities.\n16+ sessions with 75% of speakers from big pharma companies.\nAn agenda designed for professionals within the injectables space\, focused on the development\, implementation and application of wearable injectors and connected devices.\nThe only conference discussing wearable injectors and connected devices together\, other than our USA version of this event.\n\nThe Experience: \n\nA collaborative environment for pharma\, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.\nLearn from key industry players about new technologies\, strategies and processes for the development of wearable injectors.\nGain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.\nCreate a dialogue with industry leaders and develop a network with the key stakeholders in the market.\nDelve into the world of digital health for the healthcare sector and discuss implementation of connectivity with on-body drug delivery systems.\nExamine the importance of usability for at home injectors\, and what is needed to make a device appropriate for patient administration.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-uk/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T052313
CREATED:20240530T075147Z
LAST-MODIFIED:20240719T125600Z
UID:39187-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:4th iPSC Drug Development & Manufacturing Summit
DESCRIPTION:With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round\, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. Introducing the 4th iPSC Drug Development & Manufacturing Summit\, your longest standing and definitive iPSC focused platform. \nNo iPSC stone will be left unturned\, as key industry experts including Kenai Therapeutics\, Cytovia Therapeutics\, Aspen Neuroscience\, NIST and many more\, unite under one roof to transform the future of iPSC cell therapies. For the first time in 4 years\, uniting R&D teams\, manufacturing experts and business leaders\, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions. Take a look at the full session details today. \nWith all this and more\, don’t miss this golden opportunity to help you and your entire team stay at the forefront of the iPSC cell therapy revolution!
URL:https://www.pharmajournalist.com/event/4th-ipsc-drug-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T052313
CREATED:20240522T154559Z
LAST-MODIFIED:20240829T193857Z
UID:39134-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:6th Macrophage-Directed Therapies Summit
DESCRIPTION:Learning From the Past & Spearheading Macrophage Clinical Acceleration \nThe 6th Macrophage-Directed Therapies Summit is uniting 60+ biopharma and academia leaders across R&D\, Discovery\, Biology\, Translational\, and Clinical Development fields for invaluable networking and insights into all facets of macrophage-directed therapies. \nGrab your Full Agenda – https://ter.li/nqf2qd \nDespite toxicity concerns for CD47 targets in 2023\, the macrophage community persists in exploring innovative targets. Their determination to unveil new data showcasing safety and proof of concept remains stronger than ever\, revitalizing momentum in this highly promising industry. \nThis October\, you could meet leading experts from Verseau Therapeutics\, Inceptor Bio\, Carisma Therapeutics\, Elpiscience Biopharmaceuticals\, John Hopkins School of Medicine\, Resolution Therapeutics\, and more\, offering exclusive insights into their winning strategies for staying ahead of the curve in the years ahead. \nKey Highlights: \n\nTackling challenges in delivery\, administration\, animal model selection\, reprogramming\, manufacturing\, and more to optimize choices\nExploring indications for extending beyond oncology to autoimmunity\, inflammation\, neurodegenerative diseases\, and beyond\nAssessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data\n\nRegister Here for the Best Savings – https://ter.li/o22pxt
URL:https://www.pharmajournalist.com/event/6th-macrophage-directed-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T052313
CREATED:20240819T231802Z
LAST-MODIFIED:20240819T231802Z
UID:39620-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:8th MASH Drug Development Summit
DESCRIPTION:With Rezdiffra’s approval\, GLPs moving into the space\, and the wave of promising therapeutics in phrase I-III trials\, MASH therapeutics have seen an unprecedented boom in recent months. \nDon’t miss the 8th MASH Drug Development Summit’s industry-specific curated agenda spanning preclinical\, translational\, clinical and regulatory MASH developments designed to help you to overcome barriers in the development and commercialization of MASH therapies. \nWhat are the top program features to look forward to in 2024? \n\nDelve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with BMS\, Pfizer and AstraZeneca\nAccelerate your clinical trial design by optimizing cirrhosis\, MASH and fibrosis targets in trials with AstraZeneca and 89Bio\nExamine how GLP-1s can be leveraged in MASH to combat the disease drivers with Altimmune and Seal Rock Therapeutics\nExplore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca\nLeverage AI techniques and real-world evidence to integrate data\, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca\n\nFind out more here. \nThis is a conversation you won’t want to miss! Discover pricing and registation information here to discover how you can harness competitive intelligence from 3 days of cutting-edge content to supercharge your MASH therapeutic pipeline.
URL:https://www.pharmajournalist.com/event/8th-mash-drug-development-summit/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T052313
CREATED:20240815T165629Z
LAST-MODIFIED:20240815T165629Z
UID:39596-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:AI for Pharma & Healthcare Summit
DESCRIPTION:Join us for an exploration of accelerating drug development\, streamlining clinical trials and enhancing supply chain efficiency to elevate patient care across the entire value stream at the AI for Pharma & Healthcare Summit! \nImagine a world where drug discovery moves at unprecedented speeds\, clinical trials are streamlined for efficiency\, and regulatory approvals are faster than ever before. Extend that vision to manufacturing and supply chain processes enhanced by machine learning and predictive analytics to ensure that treatment reaches patients not only quicker but also more safely and reliably. This is the future of pharmaceuticals\, where advanced technology enhances every facet of patient care. \nThe transformative potential of AI is reflected in the sector’s financial outlook: the market for AI in Pharma is expected to grow exponentially\, from $3.05 billion to $18.06 billion by 2029. Yet\, amid the excitement\, a healthy dose of scepticism about the “AI Hype” exists. Pharma professionals understand the power of the technology\, but translating potential into reality requires navigating significant challenges. Pharma IQ’s AI for Pharma & Healthcare Summit aims to address these challenges by going beyond the hype\, presenting real-world AI use cases in drug discovery\, clinical trials and supply chain / manufacturing.
URL:https://www.pharmajournalist.com/event/ai-for-pharma-healthcare-summit/
LOCATION:Amsterdam Marriot Hotel\, Stadhouderskade 12\, Amsterdam\, 1054 ES\, Netherlands
ORGANIZER;CN="IQPC Ltd":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T052313
CREATED:20240704T165308Z
LAST-MODIFIED:20240704T165357Z
UID:39340-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:6th RAS-Targeted Drug Development Summit
DESCRIPTION:The race to target the remaining RAS mutants continues\, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever\, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility\, but a reality. \nAs the leading industry-centered forum\, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies\, from discovery through to clinical development\, to create effective frontline RAS therapies for cancer and better patient outcomes. \nOver three jam-packed days\, 38+ leading stakeholders will exhibit breakthrough novel data\, latest clinical advancements\, proof-of-concept\, and strategic perspectives\, all armed to improve the standard of care for patients in need. \nThis year’s summit will tackle some of the hottest advances and burning questions in the space\, such as: \n\nTargeting more mutants with RAS(ON) form\, pan-RAS approaches\, and non-canonical targets to combat cancers beyond NSCLC\nDefeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient\nShowcasing vaccines\, cell therapies\, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence\nInvestigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1\, MEK\, RAF\, and ERK\n\nJoin 200+ of your biopharma and academic peers from Early Discovery\, Translational Oncology\, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes. \nTo know more visit: https://ter.li/hosjv6
URL:https://www.pharmajournalist.com/event/6th-ras-targeted-drug-development-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260515T052313
CREATED:20240618T121731Z
LAST-MODIFIED:20240618T121731Z
UID:39302-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:2nd ADC Process Development Summit
DESCRIPTION:With cutting-edge strategies and industry insights\, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield\, optimize purification\, and streamline production to meet regulatory standards all whilst minimizing costs and timelines. \nJoin AstraZeneca\, Bristol Myers Squibb\, Pfizer and a community of industry experts in process development\, conjugation\, purification\, control\, CMC\, and engineering. With a focused discussion on process development challenges\, innovative solutions and practical takeaways\, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process. \nThis Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF\, implement rigorous control strategies for superior drug substance quality\, develop scalable processes to cut unit operations\, accelerate production timelines\, and navigate regulatory landscapes with ease. \nDon’t miss this Summit\, where innovation meets implementation\, ensuring your ADC process development reaches its optimal efficacy and efficiency!
URL:https://www.pharmajournalist.com/event/2nd-adc-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR